Trial Profile
Multicentric, Prospective, Non-Interventional Long-Term Registry Study to Describe the Safety and Importance of Gilenya (Fingolimod 05.mg) in the Treatment of Multiple Sclerosis Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PANGAEA
- Sponsors Novartis
- 12 Oct 2018 Interim results (n=77) assessing efficacy of fingolimod in two subgroups of young adult less than 20 and 30 years of age presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 12 Oct 2018 Interim results assessing treatment effectiveness of fingolimod in relapsing remitting multiple sclerosis patients treated for 5 years in clinical practice, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 12 Oct 2018 Interim results on the safety of fingolimod and persistency of patients treated with fingolimod for up to 5 years in daily clinical practice in Germany presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis